David A. Siegel Bicycle Therapeutics PLC Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 46,600 shares of BCYC stock, worth $943,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,600

Previous 62,207 25.09%

Holding current value

$943,183

Previous $1.12 Million 3.2%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $261,417 - $407,342	-15,607 Reduced 25.09%	46,600 $1.16 Million
Q4 2023 Feb 14, 2024	SELL	$13.29 - $22.2 $112,871 - $188,544	-8,493 Reduced 12.01%	62,207 $1.12 Million
Q3 2023 Nov 14, 2023	SELL	$19.9 - $26.25 $1.37 Million - $1.8 Million	-68,700 Reduced 49.28%	70,700 $1.42 Million
Q2 2023 Aug 14, 2023	SELL	$18.95 - $28.67 $919,075 - $1.39 Million	-48,500 Reduced 25.81%	139,400 $3.56 Million
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $522,522 - $818,757	26,100 Added 16.13%	187,900 $4 Million

Q4 2022 Feb 14, 2023	SELL	$20.37 - $32.9 $2.06 Million - $3.32 Million	-100,900 Reduced 38.41%	161,800 $4.79 Million
Q3 2022 Nov 14, 2022	SELL	$17.49 - $28.44 $2.67 Million - $4.34 Million	-152,500 Reduced 36.73%	262,700 $6.11 Million
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $3.71 Million - $13.5 Million	286,400 Added 222.36%	415,200 $6.97 Million
Q1 2022 May 16, 2022	BUY	$40.12 - $59.5 $1.27 Million - $1.88 Million	31,600 Added 32.51%	128,800 $5.65 Million
Q4 2021 Feb 14, 2022	BUY	$41.7 - $61.14 $2.11 Million - $3.09 Million	50,500 Added 108.14%	97,200 $5.92 Million
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $1.31 Million - $2.07 Million	46,700 New	46,700 $1.94 Million

Others Institutions Holding BCYC

# of Institutions

Shares Held

30.6M

Call Options Held

85.5K

Put Options Held

11.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $601M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account